-

One A Day® Partners with Julian Edelman to Share #WellnessConfessionals

Social campaign gives consumers a platform to divulge wellness fads they have been falling for

WHIPPANY, N.J.--(BUSINESS WIRE)--One A Day®, the multivitamin and supplement brand rooted in 80+ years of nutritional science, has launched a new campaign to address the prevalence of wellness fads and misinformation and remind consumers to trust science when it comes to their wellness journey. The social campaign #WellnessConfessionals also gives people a platform to divulge the wellness fads they have been falling for.

To support the launch of #WellnessConfessionals, One A Day® teamed up with former professional football player and MVP Julian Edelman who shares wellness trends he tried that did not live up to the hype. "People have suggested a lot of strange wellness diets to me. I’ve tried it all. But I've learned to ignore all the weird nutrition advice and build habits based in science, like eating healthy and adding One A Day®," says Edelman.

By sharing their wellness confessionals across TikTok, Instagram, and Facebook, consumers can enter a sweepstakes for a chance to win a 5-night stay at an American wellness resort to help them escape the noise.

Consumers can enter the sweepstakes by posting a video or image and sharing an experience with a wellness trend they have participated in that didn’t live up to the hype or otherwise did not meet their expectations on Facebook, Instagram or TikTok, tagging One A Day® and using the hashtag #WellnessConfessionals and #OneADaySweepstakes in the post caption. The sweepstakes run from May 9, 2024 through June 30, 2024. No purchase necessary. Void where prohibited. Open to continental U.S. residents who are least 18 years old or age of majority. For official rules, visit: https://www.oneaday.com/wellness-confessionals-giveaway-rules.

In the battleground of wellness and nutrition, new trends often promise quick fixes, whether it's detox teas, extreme diets, or trendy workouts. Many of these fads lack scientific backing and may even be harmful in the long run. "One A Day® is a multivitamin and supplement brand rooted in nutritional science, supporting consumers’ wellness for over 80 years. In a world inundated with wellness noise, One A Day® is committed to help consumers navigate the wellness noise and provide them with scientifically designed products to support their health and wellness," said Lisa Perez, General Manager and VP Marketing, Nutritionals at Bayer.

For more information on One A Day® and #WellnessConfessionals visit oneaday.com or Instagram and TikTok.

About One A Day

One A Day is a multivitamin and supplement brand offering specially formulated products for many members of the family. From prenatal to 65+, One A Day offers products for different ages, genders and health goals. The portfolio includes tablet, softgel, capsule, and gummy products. One A Day products are available at most major drugstores and retailers nationwide.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2023, the Group employed around 100,000 people and had sales of 47.6 billion euros. R&D expenses before special items amounted to 5.8 billion euros. For more information, go to www.bayer.com.

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Contacts

Jan Schlegelmilch
Director, Integrated Communications, Bayer Consumer Health U.S.
jan.schlegelmilch@bayer.com

Emma McCormick
Senior Account Supervisor, Media & Engagement, twelvenote agency
emccormick@twelvenote.com

Bayer


Release Versions

Contacts

Jan Schlegelmilch
Director, Integrated Communications, Bayer Consumer Health U.S.
jan.schlegelmilch@bayer.com

Emma McCormick
Senior Account Supervisor, Media & Engagement, twelvenote agency
emccormick@twelvenote.com

More News From Bayer

Monsanto unanimously wins first Roundup™ trial since U.S. Supreme Court decision

ST. LOUIS--(BUSINESS WIRE)--A Missouri Circuit Court jury today reached a unanimous defense verdict in favor of Monsanto in the three-plaintiff case of Theresa Aretino, et al. v. Monsanto Company, the first Roundup™ trial to take place since the U.S. Supreme Court’s landmark ruling in Monsanto v. Durnell. The jury found for Monsanto on the design defect, fraud and negligence claims that each of the three plaintiffs pursued at trial following the Supreme Court’s favorable decision in Durnell, wh...

Bayer Shares New Post Hoc Analysis Of Self-Reported Sleep-Related Outcomes with Lynkuet® (elinzanetant) in Women with Moderate to Severe Vasomotor Symptoms at the Menopause Society Annual Meeting

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced a new post hoc sub-analysis of key secondary endpoint data from the OASIS-1 and OASIS-2 pivotal trials for Lynkuet® (elinzanetant) 60mg capsules at 2026 The Menopause Society (TMS) Annual Meeting. In this sub-analysis, data from one of the key secondary endpoints, Patient-Reported Outcomes Measurement Information System Sleep Disturbance Short Form 8b (PROMIS SD SF 8b), was analyzed to further evaluate the effect of Lynkuet on sleep disturbance i...

ESMO 2026: NUBEQA® (darolutamide) Plus ADT and Radiation Therapy Reduces Risk of Metastasis or Death by 58% in Prostate Cancer Patients at High Risk of Recurrence

WHIPPANY, N.J.--(BUSINESS WIRE)--ESMO 2026: NUBEQA® plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence...
Back to Newsroom